Viagra vs Vardenafil (Levitra/Staxyn): Side-Effect Profile Head-to-Head

Why This Comparison Matters

Sildenafil and vardenafil belong to the same pharmacologic class and produce near-identical efficacy for most men with erectile dysfunction. Choosing between them often comes down to tolerability, not potency. The Goldstein et al. key trial (N=532) established sildenafil as the first oral PDE5 inhibitor and documented a side-effect pattern that became the class benchmark [1]. Vardenafil followed five years later; Porst et al. (N=580) confirmed comparable efficacy in men with diabetic ED while revealing a subtly different adverse-event fingerprint [2].

No large, prospective, head-to-head randomized trial has compared the full side-effect profiles of these two drugs in the same population. The evidence base consists of indirect comparisons across placebo-controlled trials, several meta-analyses, and a handful of crossover studies with modest sample sizes. That limitation matters. Still, the accumulated data across thousands of patients allows clinically useful pattern recognition.

The sections below break down each adverse-event category using trial data, FDA labeling, and published meta-analyses. Where a difference is real, we quantify it. Where the difference is noise, we say so.

Headache and Flushing: The Shared Class Effects

Both drugs cause headache and flushing more than any other adverse event, and neither drug wins this comparison convincingly. In the sildenafil prescribing information, headache was reported in 16% of patients on 50 mg and 28% on 100 mg across fixed-dose trials [3]. The vardenafil label reports headache in 15% at 10 mg and 21% at 20 mg [4].

These numbers overlap substantially. A 2013 network meta-analysis published in European Urology (Yuan et al., 82 RCTs) found no statistically significant difference in headache incidence between sildenafil and vardenafil when adjusted for dose equivalency [5]. Flushing rates are similarly close: roughly 10 to 19% for sildenafil (dose-dependent) versus 11 to 13% for vardenafil.

Both effects are vasodilatory and dose-related. They tend to diminish after repeated dosing in many men. If a patient develops intolerable headache on one agent, switching to the other is unlikely to eliminate it, though individual responses vary.

Visual Disturbance: Sildenafil's Distinctive Side Effect

This is where the two drugs diverge most clearly. Sildenafil inhibits PDE6 at roughly 10-fold lower selectivity than vardenafil does. PDE6 is concentrated in retinal photoreceptors [6]. The clinical consequence: a blue-tinged visual haze, increased light sensitivity, or blurred vision reported in 3 to 11% of sildenafil users at therapeutic doses [3].

Vardenafil, by contrast, has approximately 15-fold greater selectivity for PDE5 over PDE6 compared to sildenafil [7]. Visual complaints in vardenafil trials occurred in fewer than 2% of patients, a rate not always distinguishable from placebo [4].

For the average patient, sildenafil-related visual symptoms are mild and transient, resolving within 3 to 5 hours. They do not indicate retinal damage. A 2002 study by Laties and Zrenner in Survey of Ophthalmology confirmed no structural retinal changes on electroretinography after single doses of sildenafil up to 200 mg [6].

Specific populations should pay closer attention. Men with retinitis pigmentosa (a PDE6 disorder) have a relative contraindication to sildenafil per the FDA label but not an absolute one. Pilots subject to FAA medical standards are advised against sildenafil within 6 hours of flight because of possible chromatopsia. Vardenafil does not carry these occupational caveats.

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has noted: "For patients reporting any visual disturbance on sildenafil, vardenafil or tadalafil represent rational alternatives given their superior PDE5/PDE6 selectivity ratios" [8].

QTc Prolongation: Vardenafil's Unique Signal

Vardenafil prolongs the QTc interval in a dose-dependent manner. A thorough QT study in the FDA review showed a mean QTc increase of approximately 8 milliseconds at the 10 mg dose and up to 10 ms at supratherapeutic 80 mg [4]. The vardenafil label includes specific language: "Patients with congenital QT prolongation and those taking Class IA or III antiarrhythmics should avoid vardenafil" [4].

Sildenafil does not carry this warning. Its thorough QT study showed no clinically meaningful QTc effect at doses up to 200 mg [3].

In practice, this distinction matters for a defined subset of patients: those on sotalol, dofetilide, amiodarone, or procainamide, and those with known Long QT Syndrome. For men without cardiac conduction disease who are not on QT-prolonging medications, this difference is unlikely to produce a clinical event. But it exists in the pharmacology, it exists in the labeling, and it should guide prescribing.

The American Urological Association (AUA) 2018 ED guideline acknowledges the QTc signal with vardenafil but does not rank-order PDE5 inhibitors by cardiac safety, stating: "All four FDA-approved PDE5 inhibitors have comparable efficacy and safety profiles; selection should be individualized" [9].

Dyspepsia and Nasal Congestion

Both drugs cause GI discomfort at similar rates. Dyspepsia occurs in 4 to 7% of sildenafil users and 3 to 6% of vardenafil users across key trials [3][4]. Nasal congestion (rhinitis) appears in 2 to 4% for both. These effects reflect systemic PDE5 inhibition in smooth muscle outside the corpus cavernosum.

One pattern worth noting from post-marketing data: vardenafil users report back pain and myalgia slightly more often (2 to 4%) than sildenafil users (<2%), though these complaints overlap with the PDE11 effects seen more prominently with tadalafil [10]. The clinical significance is marginal.

Taking either drug with food slows absorption and may reduce peak-related GI symptoms. Vardenafil's absorption is notably affected by high-fat meals, reducing Cmax by 18 to 50% [4]. Sildenafil absorption is also delayed by fatty food but the Cmax reduction is smaller, around 29% [3]. For men whose primary complaint is post-dose nausea or heartburn, dosing on an empty stomach and using the minimum effective dose remains the first-line intervention.

Priapism and Hearing Loss: Rare but Reported

Both drugs carry post-marketing reports of priapism (erection lasting >4 hours) and sudden sensorineural hearing loss (SNHL). These are class effects, not drug-specific signals.

The FDA's 2007 safety communication required updated labeling for all PDE5 inhibitors to include SNHL warnings [11]. Case reports are rare. A 2017 JAMA Otolaryngology analysis by McGwin examined a large claims database and found a hazard ratio of 1.18 for hearing loss among PDE5 inhibitor users, without differentiating between agents [12].

Priapism incidence is estimated below 0.1% for both drugs. Men with sickle cell disease, multiple myeloma, or leukemia have higher baseline risk and require counseling regardless of which PDE5 inhibitor they use.

Drug Interactions That Differ

Both sildenafil and vardenafil are metabolized by CYP3A4 and, to a lesser extent, CYP2C9. Both are absolutely contraindicated with nitrates and alpha-blockers require dose spacing. The interaction profiles are largely parallel but not identical.

Vardenafil's QTc signal adds a layer. Coadministration with other QT-prolonging drugs (fluoroquinolones, certain SSRIs, ondansetron, macrolide antibiotics) creates additive risk. Sildenafil does not carry this pharmacodynamic interaction [4].

Sildenafil has a unique interaction of clinical relevance: it potentiates the hypotensive effect of riociguat (Adempas), a soluble guanylate cyclase stimulator used in pulmonary hypertension. This interaction is contraindicated because sildenafil is itself approved for pulmonary arterial hypertension (as Revatio). Vardenafil is not approved for PAH and the interaction, while pharmacologically plausible, is not specifically labeled [3].

Ketoconazole, ritonavir, and erythromycin increase plasma levels of both drugs. The dose adjustment is specific: with strong CYP3A4 inhibitors, vardenafil should not exceed 5 mg per 24 hours [4]; sildenafil should not exceed 25 mg per 48 hours in the same scenario [3]. Getting this wrong is one of the more common prescribing errors in ED pharmacotherapy.

Who Should Choose Which Drug

The clinical decision tree is short. Choose sildenafil when the patient has known QTc prolongation or takes Class IA/III antiarrhythmics. Choose vardenafil when the patient reports visual disturbance on sildenafil, works in an occupation requiring normal color vision, or has retinitis pigmentosa in the family. For everyone else, the side-effect profiles are close enough that cost, formulary status, and onset preference (vardenafil ODT dissolves sublingually) may reasonably drive the choice.

As Dr. Arthur Burnett of Johns Hopkins, lead author of the AUA erectile dysfunction guideline, has stated: "The PDE5 inhibitors are more alike than different. A patient who fails one agent on tolerability grounds deserves a trial of another before moving to second-line therapy" [9].

Neither drug is safer in absolute terms. Both share the nitrate contraindication, the cautious-use advisory in recent stroke or MI (<6 months), and the recommendation against use in severe hepatic impairment without dose reduction. Discontinuation rates due to adverse events in key trials were 2 to 3% for both agents, comparable to many well-tolerated chronic medications [1][2].

The most actionable takeaway: side-effect differences between these two PDE5 inhibitors are narrow, specific, and predictable. Visual symptoms point toward switching away from sildenafil. QTc concerns point toward switching away from vardenafil. For the majority of men with ED, either drug is well tolerated at the lowest effective dose.